<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427661</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #0504048</org_study_id>
    <nct_id>NCT00427661</nct_id>
  </id_info>
  <brief_title>A Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen</brief_title>
  <official_title>A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With High Risk Hemoglobinopathy Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis 1: A novel nonmyeloablative condition regimen will be safe and efficacious in
      producing stable donor chimerism and cure of severe hemoglobinopathy.

      Hypothesis 2: Stable donor chimerism will result in amelioration of cerebral vasculopathy,
      improved cerebral perfusion and neurocognitive function.

      Specific Aim 1: Study the safety and efficacy of a novel non-toxic conditioning regimen for
      HSCT for patients with severe hemoglobinopathies and the kinetics of lineage specific
      chimerism after HSCT

      We will test our hypothesis that a novel nonmyeloablative condition regimen will be safe and
      efficacious in producing stable donor chimerism and cure of severe hemoglobinopathy:

      Specific Aim 2: Optimize the immunosuppressive regimen for HSCT patients through a thorough
      understanding of the pharmacokinetics of Busulfan (BU) and mycophenolate mofetil (MMF) in the
      patient population. This will involve:

        1. Determine the pharmacokinetics of intravenously and orally administered MMF and
           intravenous BU in patients receiving HSCT.

        2. Determine the relationship of Area under the curve (AUC) of BU and mean trough
           concentrations of mycophenolic acid (MPA) to engraftment and graft versus host disease
           (GVHD).

        3. Determine the relationship of Area under the curve (AUC) and steady state concentration
           of BU to engraftment at day 30 and 1 year post HSCT.

      Specific Aim 3: Study the effect of complete or partial donor chimerism on silent and overt
      cerebral vasculopathy, and neurocognitive functioning in patients with SCD undergoing HSCT.
      We will test our hypothesis that stable donor chimerism will result in improvement in
      cerebral vasculopathy and neurocognitive function. This will include.

        1. Determine effect of transplantation silent and overt cerebral vasculopathy by comparison
           MRA and TCD 1 year after HSCT to pre-HSCT studies.

        2. Determine effect on HSCT on neurocognitive function. Specific Aim 4: To determine the
           rate of T cell immune reconstitution in children with sickle cell disease following
           myeloablative compared to nonmyeloablative stem cell transplantation, using
           immunophenotyping assays, CDR3 spectratyping TREC analysis, and measurement of T cell
           specific donor engraftment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe hemoglobinopathies such as sickle cell disease (SCD) and Thalassemia are associated
      with considerable morbidity, organ damage and premature mortality. Allogeneic hematopoietic
      stem cell transplantation (HSCT) is the only therapy that can cure a hemoglobinopathy. The
      applicability of HSCT for hemoglobinopathies is limited by the paucity of suitable donors,
      and risk of early regimen-related toxicity and the late effects. Reduction of the dose of
      myelotoxic drugs in preparative regimens prior to HSCT has the potential to increase the
      applicability of this curative option for patients with hemoglobinopathies. We hypothesize
      that a preparative regimen that maximizes host immunosuppression without myeloablation will
      be well tolerated and sufficient for engraftment of donor hematopoietic stem cells in
      patients with severe hemoglobinopathies. The long term objective of this research is to
      develop novel, less toxic approaches to HSCT for patients with severe hemoglobinopathies.
      Specific aims: 1. To evaluate the safety and efficacy of a novel nontoxic nonmyeloablative
      approach to hematopoietic stem cell transplantation for hemoglobinopathies. 2. To optimize
      the immunosuppressive regimen for HSCT patients through a thorough understanding of the
      pharmacokinetics of Busulfan (BU) and Mycophenolic acid (MPA) 3. To determine the effect of
      partial or complete donor chimerism on cerebral vasculopathy in patients with SCD. 4. To
      determine the rate of T cell immune reconstitution in children with sickle cell disease
      following myeloablative compared to nonmyeloablative stem cell transplantation, using
      immunophenotyping assays, CDR3 spectratyping TREC analysis, and measurement of T cell
      specific donor engraftment. Subjects meeting eligibility criteria in whom an human leukocyte
      antigen matched, partially mismatched related or unrelated donor of bone marrow or umbilical
      cord blood will receive a HSCT after a nonmyeloablative preparative regimen consisting of BU,
      Fludarabine (FLU), total lymphoid radiation and Anti-Thymocyte globulin followed by
      prophylaxis against graft versus host disease with cyclosporine A and MMF. Patients will be
      studied for survival, cure of hemoglobinopathy, absence of severe regimen related toxicity
      and graft versus host disease. The relationship of engraftment, survival and Graft versus
      host disease to kinetics of lineage specific donor chimerism and area under the curve for
      Mycophenolic acid and Busulfan will be studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of GVHD Within 1 Year of BMT</measure>
    <time_frame>1 year</time_frame>
    <description>GVHD is assessed by physical exam, bloodwork and biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Engraftment at 1 Year Post BMT.</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement of total PBMC chimerism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 2-4 Acute GVHD.</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Thalassemia</condition>
  <condition>Hemoglobinopathies</condition>
  <arm_group>
    <arm_group_label>AHCT in High Risk SCD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention: Busulfan; Fludarabine; cyclosporine A and MMF</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Busulfan; Fludarabine; cyclosporine A and MMF</intervention_name>
    <description>Hematopoietic stem cell transplantation from a matched sibling or unrelated donor following a reduced intensity conditioning regimen</description>
    <arm_group_label>AHCT in High Risk SCD</arm_group_label>
    <other_name>Busulfex, Fludara, Gengraf, CellCept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with SCD 0-35 years of age with an HLA-identical or 1 HLA antigen mismatched
             bone marrow or up to 2 HLA antigen mismatched umbilical cord blood (UCB) donor with
             one or more of the following:

               -  Stroke, CNS hemorrhage or a neurologic event lasting longer than 24 hours, or
                  abnormal cerebral MRI or cerebral arteriogram or MRI angiographic study and
                  impaired neuropsychological testing,

               -  Acute chest syndrome with a history of recurrent hospitalizations or exchange
                  transfusions,

               -  Recurrent vaso-occlusive pain 3 or more episodes per year for 3 years or more
                  years or recurrent priapism,

               -  Impaired neuropsychological function and abnormal cerebral MRI scan,

               -  Stage I or II sickle lung disease,

               -  Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration
                  rate [GFR] 30-50% of the predicted normal value),

               -  Bilateral proliferative retinopathy and major visual impairment in at least one
                  eye,

               -  Osteonecrosis of multiple joints with documented destructive changes,

               -  Requirement for chronic transfusions but with RBC alloimmunization &gt;2 antibodies
                  during long term transfusion therapy.

               -  Patients with transfusion dependent Thalassemia 0-35 years of age with an
                  HLA-identical or 1 HLA antigen mismatched bone marrow or up to 2 HLA antigen
                  mismatched UCB donor.

          -  Second Transplants

               -  Patients with sickle cell disease or Thalassemia who have failed to engraft or
                  have autologous recovery are eligible for this protocol.

               -  Patients must meet above criteria.

               -  If first transplant was a non-myeloablative regimen, the second transplant can
                  occur at any time.

               -  If the first transplant was a myeloablative regimen, then the second transplant
                  must be &gt; 6 months from the first transplant.

        Exclusion Criteria:

          -  Patients with one or more of the following:

               -  Karnofsky or Lansky performance score &lt;70,

               -  Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on
                  biopsy,

               -  Stage III-IV lung disease,

               -  GFR&lt;30% predicted normal values.

               -  Pregnant or lactating females.

          -  Active serious infection whereby patient has been on intravenous antibiotics for one
             week prior to study entry. Any patient with AIDS or ARC or HIV seropositivity. Any
             patient with invasive aspergillums infection within one year of study entry.

          -  Psychologically incapable of undergoing BMT with associated strict isolation or
             documented history of medical non-compliance.

          -  Patients not able to receive TLI due to prior radiation therapy.

        Donor Inclusion Criteria

          -  Donor must be in good health based on review of systems and results of physical
             examination.

          -  Donor must have a normal hemoglobin, white count, platelet count and PTT.

          -  Female donors of childbearing potential must have a negative pregnancy test.

        Donor Exclusion Criteria

          -  Donor has active infection (including HIV, hepatitis).

          -  Donor is a lactating female.

        Donor Selection

        In the case where more than one donor meets the eligibility criteria, donor selection will
        be guided by the following considerations:

          -  HLA A, B, DRB1 identical sibling donor is preferable to an unrelated donor

          -  Homozygous normal donor is preferable to heterozygote (carrier)

          -  ABO-compatible donor is preferable to ABO-incompatible donor

          -  Younger donor is preferable to older

          -  Cytomegalovirus seronegative donor is preferable to CMV seropositive donor, if the
             patient is CMV negative
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lakshmanan Krishnamurti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2007</study_first_submitted>
  <study_first_submitted_qc>January 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <results_first_submitted>February 19, 2016</results_first_submitted>
  <results_first_submitted_qc>July 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2016</results_first_posted>
  <last_update_submitted>July 8, 2016</last_update_submitted>
  <last_update_submitted_qc>July 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Lakshmanan Krishnamurti</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Thalassemia</keyword>
  <keyword>Hemoglobinopathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AHSC in Severe SCD</title>
          <description>The patient population for this study included severe SCD patients, both pediatric and adult, who did not have end-organ failure, and met all of the eligibility criteria.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AHSC in Severe SCD</title>
          <description>The patient population for this study included severe SCD patients, both pediatric and adult, who did not have end-organ failure, and met all of the eligibility criteria.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Development of GVHD Within 1 Year of BMT</title>
        <description>GVHD is assessed by physical exam, bloodwork and biopsy.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AHSC in Severe SCD</title>
            <description>The patient population for this study included severe SCD patients, both pediatric and adult, who did not have end-organ failure, and met all of the eligibility criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Development of GVHD Within 1 Year of BMT</title>
          <description>GVHD is assessed by physical exam, bloodwork and biopsy.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Engraftment at 1 Year Post BMT.</title>
        <description>Measurement of total PBMC chimerism</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AHSC in Severe SCD</title>
            <description>The patient population for this study included severe SCD patients, both pediatric and adult, who did not have end-organ failure, and met all of the eligibility criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Engraftment at 1 Year Post BMT.</title>
          <description>Measurement of total PBMC chimerism</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade 2-4 Acute GVHD.</title>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Busulfan, Fludarabine, Cyclosporine, MMF</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade 2-4 Acute GVHD.</title>
          <units>participants with grade 2-4 AGVHD</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AHSC in Severe SCD</title>
          <description>The patient population for this study included severe SCD patients, both pediatric and adult, who did not have end-organ failure, and met all of the eligibility criteria.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Arterial Hypertension</sub_title>
                <description>21 year old female patient developed complications related to sickle cell disease associated progressive pulmonary arterial hypertension and died 10 months post BMT.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>Mild pancreatitis Day +109
(Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Poor oral intake</sub_title>
                <description>Required transient parenteral alimentation
(Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Line related bacteremia</sub_title>
                <description>line related bacteremia with Rhizobium radiobactor d100
(Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>Dermatomal herpes zoster Parainfluenza A infection
(Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Line related bacteremia</sub_title>
                <description>Line related bacteremia d244
(Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Seizure day+11 secondary to low level of phenytoin
(Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270.)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>headache day +1-+4, post transplant, requiring analgesics (Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <description>Hemoglobinuria immediately following stem cell transplant the resolved within 48 hours (Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy Harter-Administrative Director of Research</name_or_title>
      <organization>University of Pittsburgh-Department of Pediatrics</organization>
      <phone>412-692-7487</phone>
      <email>harterne@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

